Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients.
Bloodstream infection
Colonization
Hematological patients
Multi-drug resistant bacteria (MDRB)
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
19
09
2021
accepted:
12
02
2022
entrez:
22
2
2022
pubmed:
23
2
2022
medline:
24
2
2022
Statut:
epublish
Résumé
To investigate the multi-drug resistant bacteria (MDRB) colonization rate in hematological patients hospitalized for any cause using a multi-body-site surveillance approach, and determine the extent to which this screening strategy helped anticipate MDRB bloodstream infections (BSI). Single-center retrospective observational study including 361 admissions documented in 250 adult patients. Surveillance cultures of nasal, pharyngeal, axillary and rectal specimens (the latter two combined) were performed at admission and subsequently on a weekly basis. Blood culture samples were incubated in an automated continuous monitoring blood culturing instrument (BACTEC FX). In total, 3463 surveillance cultures were performed (pharyngeal, n = 1201; axillary-rectal, n = 1200; nasal, n = 1062). MDRB colonization was documented in 122 out of 361 (33.7%) admissions corresponding to 86 patients (34.4%). A total of 149 MDRB were isolated from one or more body sites, of which most were Gram-negative bacteria, most frequently non-fermenting (n = 83) followed by Enterobacterales (n = 51). BSI were documented in 102 admissions (28%) involving 87 patients. Overall, the rate of BSI caused by MDRB was significantly higher (p = 0.04) in the presence of colonizing MDRB (16 out of 47 admissions in 14 patients) than in its absence (9 out of 55 admissions in 9 patients). Colonization by any MDRB was independently associated with increased risk of MDRB-BSI (HR, 3.70; 95% CI, 1.38-9.90; p = 0.009). MDRB colonization is a frequent event in hematological patients hospitalized for any reason and is associated with an increased risk of MDRB BSI. The data lend support to the use of MDRB colonization surveillance cultures for predicting the occurrence of MDRB BSI in this cohort.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the multi-drug resistant bacteria (MDRB) colonization rate in hematological patients hospitalized for any cause using a multi-body-site surveillance approach, and determine the extent to which this screening strategy helped anticipate MDRB bloodstream infections (BSI).
METHODS
METHODS
Single-center retrospective observational study including 361 admissions documented in 250 adult patients. Surveillance cultures of nasal, pharyngeal, axillary and rectal specimens (the latter two combined) were performed at admission and subsequently on a weekly basis. Blood culture samples were incubated in an automated continuous monitoring blood culturing instrument (BACTEC FX).
RESULTS
RESULTS
In total, 3463 surveillance cultures were performed (pharyngeal, n = 1201; axillary-rectal, n = 1200; nasal, n = 1062). MDRB colonization was documented in 122 out of 361 (33.7%) admissions corresponding to 86 patients (34.4%). A total of 149 MDRB were isolated from one or more body sites, of which most were Gram-negative bacteria, most frequently non-fermenting (n = 83) followed by Enterobacterales (n = 51). BSI were documented in 102 admissions (28%) involving 87 patients. Overall, the rate of BSI caused by MDRB was significantly higher (p = 0.04) in the presence of colonizing MDRB (16 out of 47 admissions in 14 patients) than in its absence (9 out of 55 admissions in 9 patients). Colonization by any MDRB was independently associated with increased risk of MDRB-BSI (HR, 3.70; 95% CI, 1.38-9.90; p = 0.009).
CONCLUSION
CONCLUSIONS
MDRB colonization is a frequent event in hematological patients hospitalized for any reason and is associated with an increased risk of MDRB BSI. The data lend support to the use of MDRB colonization surveillance cultures for predicting the occurrence of MDRB BSI in this cohort.
Identifiants
pubmed: 35189833
doi: 10.1186/s12879-022-07154-3
pii: 10.1186/s12879-022-07154-3
pmc: PMC8862203
doi:
Substances chimiques
Anti-Bacterial Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2019 Jan 23;14(1):e0210991
pubmed: 30673776
J Med Microbiol. 2017 Dec;66(12):1752-1758
pubmed: 29134938
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
pubmed: 24329732
J Antimicrob Chemother. 2014 Dec;69(12):3387-92
pubmed: 25103492
Am J Hematol. 2016 Nov;91(11):1076-1081
pubmed: 27428072
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Bone Marrow Transplant. 2015 Feb;50(2):282-8
pubmed: 25310302
Antimicrob Resist Infect Control. 2017 Nov 15;6:113
pubmed: 29163939
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2069-2074
pubmed: 30105621
Clin Infect Dis. 2012 Oct;55(7):943-50
pubmed: 22752516
Clin Microbiol Infect. 2013 May;19(5):474-9
pubmed: 22524597
BMC Infect Dis. 2017 Mar 10;17(1):203
pubmed: 28283020
Ann Hematol. 2018 Sep;97(9):1717-1726
pubmed: 29705860
Infection. 2012 Dec;40(6):613-9
pubmed: 22665143
Front Microbiol. 2020 Jul 17;11:1422
pubmed: 32765433
Emerg Infect Dis. 2014 Jul;20(7):1235-6
pubmed: 24960464
Ann Hematol. 2018 Mar;97(3):509-517
pubmed: 29255911
Clin Microbiol Infect. 2015 Dec;21(12):1057-66
pubmed: 26435462
Biol Blood Marrow Transplant. 2007 May;13(5):615-21
pubmed: 17448922
J Antimicrob Chemother. 2011 Mar;66(3):657-63
pubmed: 21193475
J Hosp Infect. 1997 Dec;37(4):287-95
pubmed: 9457606
Clin Infect Dis. 2014 May;58(9):1274-83
pubmed: 24463280
Enferm Infecc Microbiol Clin (Engl Ed). 2019 Aug - Sep;37(7):454-457
pubmed: 30857832
Curr Opin Infect Dis. 2014 Apr;27(2):200-10
pubmed: 24573013
Clin Microbiol Infect. 2015 Apr;21(4):337-43
pubmed: 25595706
Expert Rev Hematol. 2020 Aug;13(8):923-927
pubmed: 32574123
Infect Chemother. 2021 Mar;53(1):63-74
pubmed: 33538132
Mediterr J Hematol Infect Dis. 2018 May 01;10(1):e2018025
pubmed: 29755703
Intensive Care Med. 2008 Dec;34(12):2169-75
pubmed: 18712349